A randomized, open-label, multicenter study to assess the safety and tolerability of doripenem compared with imipenem in the treatment of subjects with complicated intra-abdominal infections or ventilator associated pneumonia.

Trial Profile

A randomized, open-label, multicenter study to assess the safety and tolerability of doripenem compared with imipenem in the treatment of subjects with complicated intra-abdominal infections or ventilator associated pneumonia.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2013

At a glance

  • Drugs Doripenem; Imipenem/cilastatin
  • Indications Bacterial infections; Intra-abdominal infections; Nosocomial pneumonia
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 03 Jul 2012 Additional trial location (France) and associations (Janssen Cilag International, MSD Polska, Shionogi and Company) added as reported by European Clinical Trials Database record.
    • 18 Apr 2009 Patient numbers amended from 250 to 144 as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top